Search

Your search keyword '"Monzani G"' showing total 41 results
Start Over Author "Monzani G"
41 results on '"Monzani G"'

1. The novel Mechanical Ventilator Milano for the COVID-19 pandemic

Author

Abba, A, Accorsi, C, Agnes, P, Alessi, E, Amaudruz, P, Annovi, A, Desages, F, Back, S, Badia, C, Bagger, J, Basile, V, Batignani, G, Bayo, A, Bell, B, Beschi, M, Biagini, D, Bianchi, G, Bicelli, S, Bishop, D, Boccali, T, Bombarda, A, Bonfanti, S, Bonivento, W, Bouchard, M, Breviario, M, Brice, S, Brown, R, Calvo-Mozota, J, Camozzi, L, Camozzi, M, Capra, A, Caravati, M, Carlini, M, Ceccanti, A, Celano, B, Cela Ruiz, J, Charette, C, Cogliati, G, Constable, M, Crippa, C, Croci, G, Cudmore, S, Dahl, C, Dal Molin, A, Daley, M, Di Guardo, C, D'Avenio, G, Davignon, O, Del Tutto, M, De Ruiter, J, Devoto, A, Diaz Gomez Maqueo, P, Di Francesco, F, Dossi, M, Druszkiewicz, E, Duma, C, Elliott, E, Farina, D, Fernandes, C, Ferroni, F, Finocchiaro, G, Fiorillo, G, Ford, R, Foti, G, Fournier, R, Franco, D, Fricbergs, C, Gabriele, F, Galbiati, C, Garcia Abia, P, Gargantini, A, Giacomelli, L, Giacomini, F, Giarratana, L, Gillespie, S, Giorgi, D, Girma, T, Gobui, R, Goeldi, D, Golf, F, Gorel, P, Gorini, G, Gramellini, E, Grosso, G, Guescini, F, Guetre, E, Hackman, G, Hadden, T, Hawkins, W, Hayashi, K, Heavey, A, Hersak, G, Hessey, N, Hockin, G, Hudson, K, Ianni, A, Ienzi, C, Ippolito, V, James, C, Jillings, C, Kendziora, C, Khan, S, Kim, E, King, M, King, S, Kittmer, A, Kochanek, I, Kowalkowski, J, Krucken, R, Kushoro, M, Kuula, S, Laclaustra, M, Leblond, G, Lee, L, Lennarz, A, Leyton, M, Li, X, Liimatainen, P, Lim, C, Lindner, T, Lomonaco, T, Lu, P, Lubna, R, Lukhanin, G, Luzon, G, Macdonald, M, Magni, G, Maharaj, R, Manni, S, Mapelli, C, Margetak, P, Martin, L, Martin, S, Martinez, M, Massacret, N, Mcclurg, P, Mcdonald, A, Meazzi, E, Migalla, R, Mohayai, T, Tosatti, L, Monzani, G, Moretti, C, Morrison, B, Mountaniol, M, Muraro, A, Napoli, P, Nati, F, Natzke, C, Noble, A, Norrick, A, Olchanski, K, Ortiz De Solorzano, A, Padula, F, Pallavicini, M, Palumbo, I, Panontin, E, Papini, N, Parmeggiano, L, Parmeggiano, S, Patel, K, Patel, A, Paterno, M, Pellegrino, C, Pelliccione, P, Pesudo, V, Pocar, A, Pope, A, Pordes, S, Prelz, F, Putignano, O, Raaf, J, Ratti, C, Razeti, M, Razeto, A, Reed, D, Refsgaard, J, Reilly, T, Renshaw, A, Retriere, F, Riccobene, E, Rigamonti, D, Rizzi, A, Rode, J, Romualdez, J, Russel, L, Sablone, D, Sala, S, Salomoni, D, Salvo, P, Sandoval, A, Sansoucy, E, Santorelli, R, Savarese, C, Scapparone, E, Schaubel, T, Scorza, S, Settimo, M, Shaw, B, Shawyer, S, Sher, A, Shi, A, Skensved, P, Slutsky, A, Smith, B, Smith, N, Stenzler, A, Straubel, C, Stringari, P, Suchenek, M, Sur, B, Tacchino, S, Takeuchi, L, Tardocchi, M, Tartaglia, R, Thomas, E, Trask, D, Tseng, J, Tseng, L, Vanpagee, L, Vedia, V, Velghe, B, Viel, S, Visioli, A, Viviani, L, Vonica, D, Wada, M, Walter, D, Wang, H, Wang, M, Westerdale, S, Wood, D, Yates, D, Yue, S, Zambrano, V, Abba A., Accorsi C., Agnes P., Alessi E., Amaudruz P., Annovi A., Desages F. A., Back S., Badia C., Bagger J., Basile V., Batignani G., Bayo A., Bell B., Beschi M., Biagini D., Bianchi G., Bicelli S., Bishop D., Boccali T., Bombarda A., Bonfanti S., Bonivento W. M., Bouchard M., Breviario M., Brice S., Brown R., Calvo-Mozota J. M., Camozzi L., Camozzi M., Capra A., Caravati M., Carlini M., Ceccanti A., Celano B., Cela Ruiz J. M., Charette C., Cogliati G., Constable M., Crippa C., Croci G., Cudmore S., Dahl C. E., Dal Molin A., Daley M., Di Guardo C., D'Avenio G., Davignon O., Del Tutto M., De Ruiter J., Devoto A., Diaz Gomez Maqueo P., Di Francesco F., Dossi M., Druszkiewicz E., Duma C., Elliott E., Farina D., Fernandes C., Ferroni F., Finocchiaro G., Fiorillo G., Ford R., Foti G., Fournier R. D., Franco D., Fricbergs C., Gabriele F., Galbiati C., Garcia Abia P., Gargantini A., Giacomelli L., Giacomini F., Giarratana L. S., Gillespie S., Giorgi D., Girma T., Gobui R., Goeldi D., Golf F., Gorel P., Gorini G., Gramellini E., Grosso G., Guescini F., Guetre E., Hackman G., Hadden T., Hawkins W., Hayashi K., Heavey A., Hersak G., Hessey N., Hockin G., Hudson K., Ianni A., Ienzi C., Ippolito V., James C. C., Jillings C., Kendziora C., Khan S., Kim E., King M., King S., Kittmer A., Kochanek I., Kowalkowski J., Krucken R., Kushoro M., Kuula S., Laclaustra M., Leblond G., Lee L., Lennarz A., Leyton M., Li X., Liimatainen P., Lim C., Lindner T., Lomonaco T., Lu P., Lubna R., Lukhanin G. A., Luzon G., Macdonald M., Magni G., Maharaj R., Manni S., Mapelli C., Margetak P., Martin L., Martin S., Martinez M., Massacret N., McClurg P., McDonald A. B., Meazzi E., Migalla R., Mohayai T., Tosatti L. M., Monzani G., Moretti C., Morrison B., Mountaniol M., Muraro A., Napoli P., Nati F., Natzke C. R., Noble A. J., Norrick A., Olchanski K., Ortiz De Solorzano A., Padula F., Pallavicini M., Palumbo I., Panontin E., Papini N., Parmeggiano L., Parmeggiano S., Patel K., Patel A., Paterno M., Pellegrino C., Pelliccione P., Pesudo V., Pocar A., Pope A., Pordes S., Prelz F., Putignano O., Raaf J. L., Ratti C., Razeti M., Razeto A., Reed D., Refsgaard J., Reilly T., Renshaw A., Retriere F., Riccobene E., Rigamonti D., Rizzi A., Rode J., Romualdez J., Russel L., Sablone D., Sala S., Salomoni D., Salvo P., Sandoval A., Sansoucy E., Santorelli R., Savarese C., Scapparone E., Schaubel T., Scorza S., Settimo M., Shaw B., Shawyer S., Sher A., Shi A., Skensved P., Slutsky A., Smith B., Smith N. J. T., Stenzler A., Straubel C., Stringari P., Suchenek M., Sur B., Tacchino S., Takeuchi L., Tardocchi M., Tartaglia R., Thomas E., Trask D., Tseng J., Tseng L., Vanpagee L., Vedia V., Velghe B., Viel S., Visioli A., Viviani L., Vonica D., Wada M., Walter D., Wang H., Wang M. H. L. S., Westerdale S., Wood D., Yates D., Yue S., Zambrano V., Abba, A, Accorsi, C, Agnes, P, Alessi, E, Amaudruz, P, Annovi, A, Desages, F, Back, S, Badia, C, Bagger, J, Basile, V, Batignani, G, Bayo, A, Bell, B, Beschi, M, Biagini, D, Bianchi, G, Bicelli, S, Bishop, D, Boccali, T, Bombarda, A, Bonfanti, S, Bonivento, W, Bouchard, M, Breviario, M, Brice, S, Brown, R, Calvo-Mozota, J, Camozzi, L, Camozzi, M, Capra, A, Caravati, M, Carlini, M, Ceccanti, A, Celano, B, Cela Ruiz, J, Charette, C, Cogliati, G, Constable, M, Crippa, C, Croci, G, Cudmore, S, Dahl, C, Dal Molin, A, Daley, M, Di Guardo, C, D'Avenio, G, Davignon, O, Del Tutto, M, De Ruiter, J, Devoto, A, Diaz Gomez Maqueo, P, Di Francesco, F, Dossi, M, Druszkiewicz, E, Duma, C, Elliott, E, Farina, D, Fernandes, C, Ferroni, F, Finocchiaro, G, Fiorillo, G, Ford, R, Foti, G, Fournier, R, Franco, D, Fricbergs, C, Gabriele, F, Galbiati, C, Garcia Abia, P, Gargantini, A, Giacomelli, L, Giacomini, F, Giarratana, L, Gillespie, S, Giorgi, D, Girma, T, Gobui, R, Goeldi, D, Golf, F, Gorel, P, Gorini, G, Gramellini, E, Grosso, G, Guescini, F, Guetre, E, Hackman, G, Hadden, T, Hawkins, W, Hayashi, K, Heavey, A, Hersak, G, Hessey, N, Hockin, G, Hudson, K, Ianni, A, Ienzi, C, Ippolito, V, James, C, Jillings, C, Kendziora, C, Khan, S, Kim, E, King, M, King, S, Kittmer, A, Kochanek, I, Kowalkowski, J, Krucken, R, Kushoro, M, Kuula, S, Laclaustra, M, Leblond, G, Lee, L, Lennarz, A, Leyton, M, Li, X, Liimatainen, P, Lim, C, Lindner, T, Lomonaco, T, Lu, P, Lubna, R, Lukhanin, G, Luzon, G, Macdonald, M, Magni, G, Maharaj, R, Manni, S, Mapelli, C, Margetak, P, Martin, L, Martin, S, Martinez, M, Massacret, N, Mcclurg, P, Mcdonald, A, Meazzi, E, Migalla, R, Mohayai, T, Tosatti, L, Monzani, G, Moretti, C, Morrison, B, Mountaniol, M, Muraro, A, Napoli, P, Nati, F, Natzke, C, Noble, A, Norrick, A, Olchanski, K, Ortiz De Solorzano, A, Padula, F, Pallavicini, M, Palumbo, I, Panontin, E, Papini, N, Parmeggiano, L, Parmeggiano, S, Patel, K, Patel, A, Paterno, M, Pellegrino, C, Pelliccione, P, Pesudo, V, Pocar, A, Pope, A, Pordes, S, Prelz, F, Putignano, O, Raaf, J, Ratti, C, Razeti, M, Razeto, A, Reed, D, Refsgaard, J, Reilly, T, Renshaw, A, Retriere, F, Riccobene, E, Rigamonti, D, Rizzi, A, Rode, J, Romualdez, J, Russel, L, Sablone, D, Sala, S, Salomoni, D, Salvo, P, Sandoval, A, Sansoucy, E, Santorelli, R, Savarese, C, Scapparone, E, Schaubel, T, Scorza, S, Settimo, M, Shaw, B, Shawyer, S, Sher, A, Shi, A, Skensved, P, Slutsky, A, Smith, B, Smith, N, Stenzler, A, Straubel, C, Stringari, P, Suchenek, M, Sur, B, Tacchino, S, Takeuchi, L, Tardocchi, M, Tartaglia, R, Thomas, E, Trask, D, Tseng, J, Tseng, L, Vanpagee, L, Vedia, V, Velghe, B, Viel, S, Visioli, A, Viviani, L, Vonica, D, Wada, M, Walter, D, Wang, H, Wang, M, Westerdale, S, Wood, D, Yates, D, Yue, S, Zambrano, V, Abba A., Accorsi C., Agnes P., Alessi E., Amaudruz P., Annovi A., Desages F. A., Back S., Badia C., Bagger J., Basile V., Batignani G., Bayo A., Bell B., Beschi M., Biagini D., Bianchi G., Bicelli S., Bishop D., Boccali T., Bombarda A., Bonfanti S., Bonivento W. M., Bouchard M., Breviario M., Brice S., Brown R., Calvo-Mozota J. M., Camozzi L., Camozzi M., Capra A., Caravati M., Carlini M., Ceccanti A., Celano B., Cela Ruiz J. M., Charette C., Cogliati G., Constable M., Crippa C., Croci G., Cudmore S., Dahl C. E., Dal Molin A., Daley M., Di Guardo C., D'Avenio G., Davignon O., Del Tutto M., De Ruiter J., Devoto A., Diaz Gomez Maqueo P., Di Francesco F., Dossi M., Druszkiewicz E., Duma C., Elliott E., Farina D., Fernandes C., Ferroni F., Finocchiaro G., Fiorillo G., Ford R., Foti G., Fournier R. D., Franco D., Fricbergs C., Gabriele F., Galbiati C., Garcia Abia P., Gargantini A., Giacomelli L., Giacomini F., Giarratana L. S., Gillespie S., Giorgi D., Girma T., Gobui R., Goeldi D., Golf F., Gorel P., Gorini G., Gramellini E., Grosso G., Guescini F., Guetre E., Hackman G., Hadden T., Hawkins W., Hayashi K., Heavey A., Hersak G., Hessey N., Hockin G., Hudson K., Ianni A., Ienzi C., Ippolito V., James C. C., Jillings C., Kendziora C., Khan S., Kim E., King M., King S., Kittmer A., Kochanek I., Kowalkowski J., Krucken R., Kushoro M., Kuula S., Laclaustra M., Leblond G., Lee L., Lennarz A., Leyton M., Li X., Liimatainen P., Lim C., Lindner T., Lomonaco T., Lu P., Lubna R., Lukhanin G. A., Luzon G., Macdonald M., Magni G., Maharaj R., Manni S., Mapelli C., Margetak P., Martin L., Martin S., Martinez M., Massacret N., McClurg P., McDonald A. B., Meazzi E., Migalla R., Mohayai T., Tosatti L. M., Monzani G., Moretti C., Morrison B., Mountaniol M., Muraro A., Napoli P., Nati F., Natzke C. R., Noble A. J., Norrick A., Olchanski K., Ortiz De Solorzano A., Padula F., Pallavicini M., Palumbo I., Panontin E., Papini N., Parmeggiano L., Parmeggiano S., Patel K., Patel A., Paterno M., Pellegrino C., Pelliccione P., Pesudo V., Pocar A., Pope A., Pordes S., Prelz F., Putignano O., Raaf J. L., Ratti C., Razeti M., Razeto A., Reed D., Refsgaard J., Reilly T., Renshaw A., Retriere F., Riccobene E., Rigamonti D., Rizzi A., Rode J., Romualdez J., Russel L., Sablone D., Sala S., Salomoni D., Salvo P., Sandoval A., Sansoucy E., Santorelli R., Savarese C., Scapparone E., Schaubel T., Scorza S., Settimo M., Shaw B., Shawyer S., Sher A., Shi A., Skensved P., Slutsky A., Smith B., Smith N. J. T., Stenzler A., Straubel C., Stringari P., Suchenek M., Sur B., Tacchino S., Takeuchi L., Tardocchi M., Tartaglia R., Thomas E., Trask D., Tseng J., Tseng L., Vanpagee L., Vedia V., Velghe B., Viel S., Visioli A., Viviani L., Vonica D., Wada M., Walter D., Wang H., Wang M. H. L. S., Westerdale S., Wood D., Yates D., Yue S., and Zambrano V.

Abstract

This paper presents the Mechanical Ventilator Milano (MVM), a novel intensive therapy mechanical ventilator designed for rapid, large-scale, low-cost production for the COVID-19 pandemic. Free of moving mechanical parts and requiring only a source of compressed oxygen and medical air to operate, the MVM is designed to support the long-term invasive ventilation often required for COVID-19 patients and operates in pressure-regulated ventilation modes, which minimize the risk of furthering lung trauma. The MVM was extensively tested against ISO standards in the laboratory using a breathing simulator, with good agreement between input and measured breathing parameters and performing correctly in response to fault conditions and stability tests. The MVM has obtained Emergency Use Authorization by U.S. Food and Drug Administration (FDA) for use in healthcare settings during the COVID-19 pandemic and Health Canada Medical Device Authorization for Importation or Sale, under Interim Order for Use in Relation to COVID-19. Following these certifications, mass production is ongoing and distribution is under way in several countries. The MVM was designed, tested, prepared for certification, and mass produced in the space of a few months by a unique collaboration of respiratory healthcare professionals and experimental physicists, working with industrial partners, and is an excellent ventilator candidate for this pandemic anywhere in the world.

Published
2021

2. The novel Mechanical Ventilator Milano for the COVID-19 pandemic

Author

Abba, A., primary, Accorsi, C., additional, Agnes, P., additional, Alessi, E., additional, Amaudruz, P., additional, Annovi, A., additional, Desages, F. Ardellier, additional, Back, S., additional, Badia, C., additional, Bagger, J., additional, Basile, V., additional, Batignani, G., additional, Bayo, A., additional, Bell, B., additional, Beschi, M., additional, Biagini, D., additional, Bianchi, G., additional, Bicelli, S., additional, Bishop, D., additional, Boccali, T., additional, Bombarda, A., additional, Bonfanti, S., additional, Bonivento, W. M., additional, Bouchard, M., additional, Breviario, M., additional, Brice, S., additional, Brown, R., additional, Calvo-Mozota, J. M., additional, Camozzi, L., additional, Camozzi, M., additional, Capra, A., additional, Caravati, M., additional, Carlini, M., additional, Ceccanti, A., additional, Celano, B., additional, Cela Ruiz, J. M., additional, Charette, C., additional, Cogliati, G., additional, Constable, M., additional, Crippa, C., additional, Croci, G., additional, Cudmore, S., additional, Dahl, C. E., additional, Dal Molin, A., additional, Daley, M., additional, Di Guardo, C., additional, D'Avenio, G., additional, Davignon, O., additional, Del Tutto, M., additional, De Ruiter, J., additional, Devoto, A., additional, Diaz Gomez Maqueo, P., additional, Di Francesco, F., additional, Dossi, M., additional, Druszkiewicz, E., additional, Duma, C., additional, Elliott, E., additional, Farina, D., additional, Fernandes, C., additional, Ferroni, F., additional, Finocchiaro, G., additional, Fiorillo, G., additional, Ford, R., additional, Foti, G., additional, Fournier, R. D., additional, Franco, D., additional, Fricbergs, C., additional, Gabriele, F., additional, Galbiati, C., additional, Garcia Abia, P., additional, Gargantini, A., additional, Giacomelli, L., additional, Giacomini, F., additional, Giarratana, L. S., additional, Gillespie, S., additional, Giorgi, D., additional, Girma, T., additional, Gobui, R., additional, Goeldi, D., additional, Golf, F., additional, Gorel, P., additional, Gorini, G., additional, Gramellini, E., additional, Grosso, G., additional, Guescini, F., additional, Guetre, E., additional, Hackman, G., additional, Hadden, T., additional, Hawkins, W., additional, Hayashi, K., additional, Heavey, A., additional, Hersak, G., additional, Hessey, N., additional, Hockin, G., additional, Hudson, K., additional, Ianni, A., additional, Ienzi, C., additional, Ippolito, V., additional, James, C. C., additional, Jillings, C., additional, Kendziora, C., additional, Khan, S., additional, Kim, E., additional, King, M., additional, King, S., additional, Kittmer, A., additional, Kochanek, I., additional, Kowalkowski, J., additional, Krücken, R., additional, Kushoro, M., additional, Kuula, S., additional, Laclaustra, M., additional, Leblond, G., additional, Lee, L., additional, Lennarz, A., additional, Leyton, M., additional, Li, X., additional, Liimatainen, P., additional, Lim, C., additional, Lindner, T., additional, Lomonaco, T., additional, Lu, P., additional, Lubna, R., additional, Lukhanin, G. A., additional, Luzón, G., additional, MacDonald, M., additional, Magni, G., additional, Maharaj, R., additional, Manni, S., additional, Mapelli, C., additional, Margetak, P., additional, Martin, L., additional, Martin, S., additional, Martínez, M., additional, Massacret, N., additional, McClurg, P., additional, McDonald, A. B., additional, Meazzi, E., additional, Migalla, R., additional, Mohayai, T., additional, Tosatti, L. M., additional, Monzani, G., additional, Moretti, C., additional, Morrison, B., additional, Mountaniol, M., additional, Muraro, A., additional, Napoli, P., additional, Nati, F., additional, Natzke, C. R., additional, Noble, A. J., additional, Norrick, A., additional, Olchanski, K., additional, Ortiz de Solorzano, A., additional, Padula, F., additional, Pallavicini, M., additional, Palumbo, I., additional, Panontin, E., additional, Papini, N., additional, Parmeggiano, L., additional, Parmeggiano, S., additional, Patel, K., additional, Patel, A., additional, Paterno, M., additional, Pellegrino, C., additional, Pelliccione, P., additional, Pesudo, V., additional, Pocar, A., additional, Pope, A., additional, Pordes, S., additional, Prelz, F., additional, Putignano, O., additional, Raaf, J. L., additional, Ratti, C., additional, Razeti, M., additional, Razeto, A., additional, Reed, D., additional, Refsgaard, J., additional, Reilly, T., additional, Renshaw, A., additional, Retriere, F., additional, Riccobene, E., additional, Rigamonti, D., additional, Rizzi, A., additional, Rode, J., additional, Romualdez, J., additional, Russel, L., additional, Sablone, D., additional, Sala, S., additional, Salomoni, D., additional, Salvo, P., additional, Sandoval, A., additional, Sansoucy, E., additional, Santorelli, R., additional, Savarese, C., additional, Scapparone, E., additional, Schaubel, T., additional, Scorza, S., additional, Settimo, M., additional, Shaw, B., additional, Shawyer, S., additional, Sher, A., additional, Shi, A., additional, Skensved, P., additional, Slutsky, A., additional, Smith, B., additional, Smith, N. J. T., additional, Stenzler, A., additional, Straubel, C., additional, Stringari, P., additional, Suchenek, M., additional, Sur, B., additional, Tacchino, S., additional, Takeuchi, L., additional, Tardocchi, M., additional, Tartaglia, R., additional, Thomas, E., additional, Trask, D., additional, Tseng, J., additional, Tseng, L., additional, VanPagee, L., additional, Vedia, V., additional, Velghe, B., additional, Viel, S., additional, Visioli, A., additional, Viviani, L., additional, Vonica, D., additional, Wada, M., additional, Walter, D., additional, Wang, H., additional, Wang, M. H. L. S., additional, Westerdale, S., additional, Wood, D., additional, Yates, D., additional, Yue, S., additional, and Zambrano, V., additional

Published
2021
Full Text
View/download PDF

4. Il lavoratore con lombalgia cronica ed un vizio di deambulazione che puo' influenzare la attivita' lavorativa: primi risultati di uno studio della Medicina del Lavoro della Azienda Ospedaliera San Gerardo di Monza

Author

Monzani, G, Centemeri, R, Facchetti, R, Riva, S, Latocca, R, D'ORSO, MARCO ITALO, CESANA, GIANCARLO, Monzani, G, Centemeri, R, D'Orso, M, Facchetti, R, Riva, S, Latocca, R, and Cesana, G

Subjects
MED/44 - MEDICINA DEL LAVORO, lombalgia cronica, idoneita' specifica, posturologia
Published
2015

6. Posturologia e lombalgia cronica: risultati a un anno di follow up

Author

BIGONI, MARCO, Guerrasio, S, Centemeri, R, Cossio, A, Brignoli, A, Usuelli, FG, Pagnacco, E, Monzani, G, Latocca, R, Marinoni, EC, Bigoni, M, Guerrasio, S, Centemeri, R, Cossio, A, Brignoli, A, Usuelli, F, Pagnacco, E, Monzani, G, Latocca, R, and Marinoni, E

Subjects
Lombalgia, Posturologia, Stabilometria
Published
2003

8. Hyperparathyroidism: is it really the major factor affecting glucose tolerance in uremia?

Author

Bergesio F, Bandini S, Cresci B, Monzani G, Rotella C, Conti A, Alberto Rosati, Piperno R, Messeri G, Frizzi V, and Salvadori M

Subjects
Adult, Blood Glucose, Male, Parathyroidectomy, Hyperparathyroidism, Glucose Tolerance Test, Middle Aged, Parathyroid Hormone, Reference Values, Renal Dialysis, Humans, Urea, Female, Aged, Uremia
Abstract

The effects of secondary hyperparathyroidism (sHPTH) on immunoreactive insulin (IRI) release and glucose (G) tolerance were studied in two groups of dialysis patients with normal (NPTH, n = 9) or elevated PTH levels (HPTH, n = 8), 27 +/- 24 and 660 +/- 440 pg/ml, respectively. The patients received an intravenous glucose tolerance test (IVGTT) using 0.33 g/kg of glucose solution. G, IRI and C-peptide (C-p) levels were determined calculating the G constant decay (K) and the relative incremental areas for each study. Regardless of PTH levels, all patients showed an impaired glucose tolerance (GT). IRI secretion and K values were not significantly different between the two groups. However, a significantly lower K value with a reduced (although not significant) early and late IRI secretion was found in the subgroup of patients with more severe. sHPTH (PTH: 560-1,500 pg/ml, n = 5) as compared to patients with moderate sHPTH (PTH: 87-341 pg/ml, n = 4) or normal (5-32 pg/ml, n = 8) PTH levels. No relationship was found between PTH and G, IRI or C-p levels. Our results point to a threshold limit for PTH's inhibitory effect on IRI secretion and suggest that other factors, known to affect IRI secretion and GT besides PTH levels, may modulate the role played by excess PTH levels on carbohydrate metabolism of dialysis patients.

Published
1996

9. Posturologia e lombalgia cronica: risultati a un anno di follow up

Author

Bigoni, M, Guerrasio, S, Centemeri, R, Cossio, A, Brignoli, A, Usuelli, F, Pagnacco, E, Monzani, G, Latocca, R, Marinoni, E, BIGONI, MARCO, Usuelli, FG, Marinoni, EC, Bigoni, M, Guerrasio, S, Centemeri, R, Cossio, A, Brignoli, A, Usuelli, F, Pagnacco, E, Monzani, G, Latocca, R, Marinoni, E, BIGONI, MARCO, Usuelli, FG, and Marinoni, EC

Published
2003

10. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment

Author

Bergesio, F., primary, Monzani, G., additional, Guasparini, A., additional, Ciuti, R., additional, Gallucci, M., additional, Cristofano, C., additional, Castrignano, E., additional, Cupisti, A., additional, Barsotti, G., additional, Marcucci, R., additional, Abbate, R., additional, Bandini, S., additional, Gallo, M., additional, Tosi, P.L., additional, and Salvadori, M., additional

Published
2005
Full Text
View/download PDF

12. Glycidic Tolerance in Chronic Renal Failure

Author

Ciciani, A.M., Bergesio, F., Monzani, G., Ciuti, R., Martinelli, F., Piperno, R., Baldereschi, G., Salvadori, M., Ciciani, A.M., Bergesio, F., Monzani, G., Ciuti, R., Martinelli, F., Piperno, R., Baldereschi, G., and Salvadori, M.

Abstract

No abstract, non disponibile

Published
1997

21. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia? <FN ID="fn1">This paper has not been peer reviewed</FN>

Author

Bergesio, F., Monzani, G., Ciuti, R., Pinzani, P., Fiaschi, N., Priami, F., Cirami, C., Ciccarelli, C., and Salvadori, M.

Abstract

Lipoprotein abnormalities are common in uraemia and are considered important factors for development of atherosclerosis and progression of renal disease. Reduction of total antioxidant capacity (TAC) and lipid peroxidation (LP) probably play a major role in both processes. The aim of this study was to assess the effect of renal function, dietary manipulation and lipids on TAC of uraemic patients with different chronic renal failure (CRF). Sixty patients (36M, 24F), aged 60 ± 12 years were divided into five groups according to serum creatinine levels (sCr,mg/dl)— CRFI, 1.5–3; CRFII, > 3–5.5; CRFIII, > 5.5; CRFIV, > 3 on vegetarian supplemented diet (SD); CRFV haemodialysis patients (HD)-and investigated for TAC by enhanced chemiluminescent assay, autoantibodies against oxidized LDL (oxLDLAb), lipids, apolipoprotein AI, B, Lp(a) and uric acid (UA). The results were compared to a control group of 19 people (8M, 11F), aged 52 ± 11 years with sCr &lt; 1.5. TAC increased significantly with the progression of CRF and was strongly related to both sCr and UA. Lipids and SD did not show any influence on TAC. Unexpectedly, lipid peroxidation did not correlate to TAC, neither to sCr or UA. HD accounted for a mild reduction of both TAC and LP. Patients on SD showed a marked reduction of LP as compared to patients with a similar degree of renal failure (CRF-III) but on conventional diet. Our results suggest that elevated TAC in uraemia is likely to be dependent on increased UA levels and does not seem to induce an effective protection in vivo from oxidative stress. In conclusion, TAC does not appear to be a reliable method for assessing the oxidative susceptibility of CRF patients. © 1998 John Wiley & Sons, Ltd.

Published
1998
Full Text
View/download PDF

22. Are Lipid Abnormalities Reliable Cardiovascular Risk Factors in Dialysis Patients?

Author

Bergesio, F., Ciuti, R., Salvadori, M., Galli, G.A., Monzani, G., Bertoni, E., Salerno, A., and Frizzi, V.

Abstract

Patients on chronic hemodialysis often present both hyperlipidemia and a high incidence of cardiovascular disease (CVD). Uremic hyperlipidemia has usually been regarded as one of the most important cardiovascular risk factors (CVRF) in these patients. In order to study whether the “uremia-induced” lipid abnormalities are actually associated with evidence of uremic CVD, and consequently may be considered reliable CVRF, 123 patients on chronic dialysis were reviewed for the presence of CVD and, at the same time, examined for their lipoprotein pattern and other clinical and biochemical variables.Lipids and lipoproteins did not prove helpful in our study in identifying patients with CVD. Despite the fact that they had been on dialysis for a shorter time, CVD patients were significantly older and had higher blood pressure than patients without CVD. Our data suggest that the uremia-induced lipid abnormalities are not reliable markers of CVD in dialysis patients, and support the hypothesis that dialysis per se does not accelerate the atherosclerotic process in uremic patients

Published
1989
Full Text
View/download PDF

24. The value of ultrasound as a screening procedure for urological disorders in renal failure

Author

G. Curatola, Monzani G, R. Mazzitelli, P. Cozzupoli, and Quirino Maggiore

Subjects
Adult, Male, Urologic Diseases, medicine.medical_specialty, Adolescent, Urology, Population, Disease, urologic and male genital diseases, Excretory urography, medicine, Urological Disorders, Humans, education, Child, Hydronephrosis, Aged, Ultrasonography, education.field_of_study, business.industry, Ultrasound, Middle Aged, medicine.disease, Laboratory test, Child, Preschool, Kidney Failure, Chronic, Female, Radiology, business, Pyelogram
Abstract

Renal ultrasound was evaluated as a screening procedure for urological conditions (hydronephrosis or space-occupying lesions) in 175 patients (316 kidneys) with renal failure. The final diagnosis of renal disease was based on excretory urography, ascending or translumbar pyelography, open surgical findings, clinical and laboratory test results or renal biopsies. Ultrasonic images suggestive of renal disease requiring surgery were obtained in 83 kidneys and subsequently confirmed in 67. There were 16 falsely positive and 2 falsely negative results. Assuming a 22 per cent prevalence of renal disease requiring surgery in the azotemic population, Bayes' theorem predicts that an abnormal ultrasonic test will increase the probability of surgery in a patient with renal failure from 0.22 to 0.81, while a negative test will reduce the probability from 0.22 to 0.013. Renal ultrasound is a highly effective method to screen for patients with renal failure who require contrast studies. With this means the risks and cost of contrast investigations can be reduced markedly.

Published
1983

25. Lp(a) levels: effects of progressive chronic renal failure and dietary manipulation

Author

Monzani G, Bergesio F, Ciuti R, Am, Ciciani, Martinelli F, Alberto Rosati, and Salvadori M

Subjects
Adult, Male, Diet, Vegetarian, Middle Aged, Treatment Outcome, Reference Values, Food, Fortified, Disease Progression, Humans, Kidney Failure, Chronic, Female, Amino Acids, Essential, Dietary Proteins, Aged, Lipoprotein(a)
Abstract

Patients with chronic renal failure (CRF) have an increased risk of cardiovascular disease (CVD). Elevated lipoprotein(a) (LP(a)) levels have been shown to be an important risk factor for CVD. This study examined Lp(a) changes during the progression of renal disease in patients following different dietary regimens. Fifty-seven patients with CRF of different etiology and degree (mean age 58 +/- 10 yrs) were divided into four groups according to their serum creatinine (sCr) levels. The first group had sCr 1.5-3; the second 3-6; the third6, all on a conventional low-protein diet (CLPD), and the fourth had sCr6 on a supplemented vegetarian diet (SVD). Lp(a), apoproteins AI, B, E, CII, CIII, CII/CIII, Apo A/Apo B ratios and the lipid pattern (total cholesterol (TC) and its fractions LDL, HDL, HDL3 and triglycerides) were investigated. Patients with diabetes, proteinuria1.5 g/24 h, hepatic disease or taking contraceptives or lipid lowering drugs were excluded. Results were compared with a reference group (N = 12) with sCcr1. Lp(a) concentrations increased with the progression of renal failure, and a significant correlation was observed with sCr. Despite the elevated sCr levels, patients on the SVD had an almost normal Lp(a) concentration. Only 15% of the reference group had Lp(a) levels30 mg/dl, compared to 33%, 50% and 78% of the 1st, 2nd and 3rd groups and 38% of the 4th group. No relationship was found between Lp(a), lipids or apoproteins. Our results indicate that renal function influences Lp(a) levels and suggest a SVD helps to lower them. This might be ascribed to some antioxidant factors in the SVD.

29. The novel Mechanical Ventilator Milano for the COVID-19 pandemic

Author

M. Tardocchi, P. Lu, Silvia Bonfanti, C. Fricbergs, J. M. Cela Ruiz, M. Del Tutto, R. Brown, D. Salomoni, C. Jillings, A. Visioli, A. Abba, B. Smith, P. Stringari, Valerio Ippolito, K. Olchanski, S. Yue, A. Razeto, L. Parmeggiano, M. Beschi, I. Palumbo, C. C. James, M. Daley, Andrea Bombarda, Eugenio Scapparone, T. Boccali, D. Vonica, G. Luzón, E. Panontin, Nigel Hessey, E. Elliott, O. Putignano, R. Maharaj, M. H. L. S. Wang, M. Laclaustra, A. Sher, E. Gramellini, P. Napoli, S. Parmeggiano, E. Meazzi, S. Sala, A. Muraro, T. Girma, D. Trask, A. Lennarz, F. Golf, G. Magni, C. Di Guardo, A. S. Slutsky, C. Lim, B. Shaw, C. Duma, V. Pesudo, S. Gillespie, A. Devoto, E. Guetre, L. Camozzi, B. Bell, C. E. Dahl, M. Dossi, E. Alessi, M. MacDonald, A. J. Noble, F. Ardellier Desages, O. Davignon, B. Morrison, R. D. Fournier, Alberto Annovi, S. Kuula, Elvinia Riccobene, A. Rizzi, G. Hersak, J. Bagger, S. Brice, S. Khan, L. VanPagee, P. Salvo, R. Lubna, A. Bayo, M. Bouchard, J. Romualdez, G. Bianchi, H. Wang, S. Bicelli, T. A. Mohayai, A. Dal Molin, M. Breviario, C. Ienzi, M. Carlini, K. Hayashi, G. Monzani, G. A. Lukhanin, R. J. Ford, D. Yates, B. Velghe, G. Finocchiaro, C. Charette, M.H. Kushoro, E. Sansoucy, D. Reed, Pierre-Andre Amaudruz, A. Pocar, S. Scorza, M. Camozzi, T. Reilly, C. Crippa, S. Pordes, F. Padula, S. Westerdale, C. Straubel, P. Garcia Abia, A. Shi, D. Giorgi, A. Capra, S. Shawyer, S. Martin, F. Prelz, S. Back, D. Sablone, L. Takeuchi, D. Franco, L. Martin, An. Ianni, L. Tseng, P. McClurg, M. I. Martínez, D. Wood, A. Norrick, C. Pellegrino, J. Tseng, C. Ratti, M. Constable, V. Vedia, L. M. Tosatti, L. S. Giarratana, G. Fiorillo, M. Razeti, A. Patel, C. R. Natzke, S. Manni, M. Wada, S. Tacchino, M. Paterno, P. Gorel, P. Diaz Gomez Maqueo, N. Massacret, S. Cudmore, Marco Pallavicini, A. Heavey, Gabriele Croci, E. Kim, B. Celano, G. Batignani, E. Druszkiewicz, A. L. Renshaw, L. Giacomelli, D. Walter, S. Viel, Angelo Gargantini, D. Goeldi, P. Liimatainen, N. J. T. Smith, T. Schaubel, G. Cogliati, G. Foti, C. Mapelli, F. Retriere, Giuseppe Gorini, K. Patel, R. Tartaglia, N. Papini, M. Settimo, P. Pelliccione, P. Skensved, M. Leyton, V. Basile, A. Kittmer, G. D'Avenio, D. Rigamonti, R. Krücken, F. Guescini, F. Giacomini, E. Thomas, K. Hudson, Claudio Moretti, R. Santorelli, G. Hackman, R. Gobui, L. Viviani, C. Savarese, I. Kochanek, R. Migalla, J. Rode, F. Gabriele, D. Farina, F. Ferroni, F. Di Francesco, J. M. Calvo-Mozota, M. Suchenek, G. Hockin, J. Refsgaard, J. Kowalkowski, A. Pope, T. Lomonaco, S. King, Bhaskar Sur, C. L. Kendziora, M. Caravati, A. Ceccanti, W. Hawkins, W. Bonivento, C. Fernandes, G. Leblond, M. Mountaniol, A. B. McDonald, C. Accorsi, A. Stenzler, Federico Nati, V. Zambrano, D. Bishop, M. King, A. Sandoval, X. Li, P. Margetak, P. Agnes, J. L. Raaf, J. De Ruiter, Cristiano Galbiati, Giovanni Grosso, L. Lee, A. Ortiz de Solórzano, T. Hadden, T. Lindner, D. Biagini, L. Russel, C. Badia, Abba, A., Accorsi, C., Agnes, P., Alessi, E., Amaudruz, P., Annovi, A., Desages, F. A., Back, S., Badia, C., Bagger, J., Basile, V., Batignani, G., Bayo, A., Bell, B., Beschi, M., Biagini, D., Bianchi, G., Bicelli, S., Bishop, D., Boccali, T., Bombarda, A., Bonfanti, S., Bonivento, W. M., Bouchard, M., Breviario, M., Brice, S., Brown, R., Calvo-Mozota, J. M., Camozzi, L., Camozzi, M., Capra, A., Caravati, M., Carlini, M., Ceccanti, A., Celano, B., Cela Ruiz, J. M., Charette, C., Cogliati, G., Constable, M., Crippa, C., Croci, G., Cudmore, S., Dahl, C. E., Dal Molin, A., Daley, M., Di Guardo, C., D'Avenio, G., Davignon, O., Del Tutto, M., De Ruiter, J., Devoto, A., Diaz Gomez Maqueo, P., Di Francesco, F., Dossi, M., Druszkiewicz, E., Duma, C., Elliott, E., Farina, D., Fernandes, C., Ferroni, F., Finocchiaro, G., Fiorillo, G., Ford, R., Foti, G., Fournier, R. D., Franco, D., Fricbergs, C., Gabriele, F., Galbiati, C., Garcia Abia, P., Gargantini, A., Giacomelli, L., Giacomini, F., Giarratana, L. S., Gillespie, S., Giorgi, D., Girma, T., Gobui, R., Goeldi, D., Golf, F., Gorel, P., Gorini, G., Gramellini, E., Grosso, G., Guescini, F., Guetre, E., Hackman, G., Hadden, T., Hawkins, W., Hayashi, K., Heavey, A., Hersak, G., Hessey, N., Hockin, G., Hudson, K., Ianni, A., Ienzi, C., Ippolito, V., James, C. C., Jillings, C., Kendziora, C., Khan, S., Kim, E., King, M., King, S., Kittmer, A., Kochanek, I., Kowalkowski, J., Krucken, R., Kushoro, M., Kuula, S., Laclaustra, M., Leblond, G., Lee, L., Lennarz, A., Leyton, M., Li, X., Liimatainen, P., Lim, C., Lindner, T., Lomonaco, T., Lu, P., Lubna, R., Lukhanin, G. A., Luzon, G., Macdonald, M., Magni, G., Maharaj, R., Manni, S., Mapelli, C., Margetak, P., Martin, L., Martin, S., Martinez, M., Massacret, N., Mcclurg, P., Mcdonald, A. B., Meazzi, E., Migalla, R., Mohayai, T., Tosatti, L. M., Monzani, G., Moretti, C., Morrison, B., Mountaniol, M., Muraro, A., Napoli, P., Nati, F., Natzke, C. R., Noble, A. J., Norrick, A., Olchanski, K., Ortiz De Solorzano, A., Padula, F., Pallavicini, M., Palumbo, I., Panontin, E., Papini, N., Parmeggiano, L., Parmeggiano, S., Patel, K., Patel, A., Paterno, M., Pellegrino, C., Pelliccione, P., Pesudo, V., Pocar, A., Pope, A., Pordes, S., Prelz, F., Putignano, O., Raaf, J. L., Ratti, C., Razeti, M., Razeto, A., Reed, D., Refsgaard, J., Reilly, T., Renshaw, A., Retriere, F., Riccobene, E., Rigamonti, D., Rizzi, A., Rode, J., Romualdez, J., Russel, L., Sablone, D., Sala, S., Salomoni, D., Salvo, P., Sandoval, A., Sansoucy, E., Santorelli, R., Savarese, C., Scapparone, E., Schaubel, T., Scorza, S., Settimo, M., Shaw, B., Shawyer, S., Sher, A., Shi, A., Skensved, P., Slutsky, A., Smith, B., Smith, N. J. T., Stenzler, A., Straubel, C., Stringari, P., Suchenek, M., Sur, B., Tacchino, S., Takeuchi, L., Tardocchi, M., Tartaglia, R., Thomas, E., Trask, D., Tseng, J., Tseng, L., Vanpagee, L., Vedia, V., Velghe, B., Viel, S., Visioli, A., Viviani, L., Vonica, D., Wada, M., Walter, D., Wang, H., Wang, M. H. L. S., Westerdale, S., Wood, D., Yates, D., Yue, S., Zambrano, V., AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire Leprince-Ringuet (LLR), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire de physique subatomique et des technologies associées (SUBATECH), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), École des Mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Abba, A, Accorsi, C, Agnes, P, Alessi, E, Amaudruz, P, Annovi, A, Desages, F, Back, S, Badia, C, Bagger, J, Basile, V, Batignani, G, Bayo, A, Bell, B, Beschi, M, Biagini, D, Bianchi, G, Bicelli, S, Bishop, D, Boccali, T, Bombarda, A, Bonfanti, S, Bonivento, W, Bouchard, M, Breviario, M, Brice, S, Brown, R, Calvo-Mozota, J, Camozzi, L, Camozzi, M, Capra, A, Caravati, M, Carlini, M, Ceccanti, A, Celano, B, Cela Ruiz, J, Charette, C, Cogliati, G, Constable, M, Crippa, C, Croci, G, Cudmore, S, Dahl, C, Dal Molin, A, Daley, M, Di Guardo, C, D'Avenio, G, Davignon, O, Del Tutto, M, De Ruiter, J, Devoto, A, Diaz Gomez Maqueo, P, Di Francesco, F, Dossi, M, Druszkiewicz, E, Duma, C, Elliott, E, Farina, D, Fernandes, C, Ferroni, F, Finocchiaro, G, Fiorillo, G, Ford, R, Foti, G, Fournier, R, Franco, D, Fricbergs, C, Gabriele, F, Galbiati, C, Garcia Abia, P, Gargantini, A, Giacomelli, L, Giacomini, F, Giarratana, L, Gillespie, S, Giorgi, D, Girma, T, Gobui, R, Goeldi, D, Golf, F, Gorel, P, Gorini, G, Gramellini, E, Grosso, G, Guescini, F, Guetre, E, Hackman, G, Hadden, T, Hawkins, W, Hayashi, K, Heavey, A, Hersak, G, Hessey, N, Hockin, G, Hudson, K, Ianni, A, Ienzi, C, Ippolito, V, James, C, Jillings, C, Kendziora, C, Khan, S, Kim, E, King, M, King, S, Kittmer, A, Kochanek, I, Kowalkowski, J, Krucken, R, Kushoro, M, Kuula, S, Laclaustra, M, Leblond, G, Lee, L, Lennarz, A, Leyton, M, Li, X, Liimatainen, P, Lim, C, Lindner, T, Lomonaco, T, Lu, P, Lubna, R, Lukhanin, G, Luzon, G, Macdonald, M, Magni, G, Maharaj, R, Manni, S, Mapelli, C, Margetak, P, Martin, L, Martin, S, Martinez, M, Massacret, N, Mcclurg, P, Mcdonald, A, Meazzi, E, Migalla, R, Mohayai, T, Tosatti, L, Monzani, G, Moretti, C, Morrison, B, Mountaniol, M, Muraro, A, Napoli, P, Nati, F, Natzke, C, Noble, A, Norrick, A, Olchanski, K, Ortiz De Solorzano, A, Padula, F, Pallavicini, M, Palumbo, I, Panontin, E, Papini, N, Parmeggiano, L, Parmeggiano, S, Patel, K, Patel, A, Paterno, M, Pellegrino, C, Pelliccione, P, Pesudo, V, Pocar, A, Pope, A, Pordes, S, Prelz, F, Putignano, O, Raaf, J, Ratti, C, Razeti, M, Razeto, A, Reed, D, Refsgaard, J, Reilly, T, Renshaw, A, Retriere, F, Riccobene, E, Rigamonti, D, Rizzi, A, Rode, J, Romualdez, J, Russel, L, Sablone, D, Sala, S, Salomoni, D, Salvo, P, Sandoval, A, Sansoucy, E, Santorelli, R, Savarese, C, Scapparone, E, Schaubel, T, Scorza, S, Settimo, M, Shaw, B, Shawyer, S, Sher, A, Shi, A, Skensved, P, Slutsky, A, Smith, B, Smith, N, Stenzler, A, Straubel, C, Stringari, P, Suchenek, M, Sur, B, Tacchino, S, Takeuchi, L, Tardocchi, M, Tartaglia, R, Thomas, E, Trask, D, Tseng, J, Tseng, L, Vanpagee, L, Vedia, V, Velghe, B, Viel, S, Visioli, A, Viviani, L, Vonica, D, Wada, M, Walter, D, Wang, H, Wang, M, Westerdale, S, Wood, D, Yates, D, Yue, S, and Zambrano, V

Subjects
ventilator, Emergency Use Authorization, Coronavirus disease 2019 (COVID-19), Fault conditions, Computational Mechanics, Certification, 01 natural sciences, 010305 fluids & plasmas, law.invention, Mechanical parts, Food and drug administration, Compressed oxygen, Food and Drug Administration, Health care professionals, Industrial partners, Intensive therapy, Ventilation mode, Mechanical ventilator, law, 0103 physical sciences, Pandemic, medicine, 010306 general physics, Fluid Flow and Transfer Processes, Physics, [PHYS]Physics [physics], Mechanical Engineering, healthcare, Articles, Condensed Matter Physics, medicine.disease, 3. Good health, Medical gas supply, Mechanical Ventilation, COVID-19 Pandemic, covid-19, Mechanics of Materials, Others, Ventilation (architecture), Medical emergency, Settore ING-INF/05 - Sistemi di Elaborazione delle Informazioni, [PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]
Abstract

International audience; This paper presents the Mechanical Ventilator Milano (MVM), a novel intensive therapy mechanical ventilator designed for rapid, large-scale, low-cost production for the COVID-19 pandemic. Free of moving mechanical parts and requiring only a source of compressed oxygen and medical air to operate, the MVM is designed to support the long-term invasive ventilation often required for COVID-19 patients and operates in pressure-regulated ventilation modes, which minimize the risk of furthering lung trauma. The MVM was extensively tested against ISO standards in the laboratory using a breathing simulator, with good agreement between input and measured breathing parameters and performing correctly in response to fault conditions and stability tests. The MVM has obtained Emergency Use Authorization by U.S. Food and Drug Administration (FDA) for use in healthcare settings during the COVID-19 pandemic and Health Canada Medical Device Authorization for Importation or Sale, under Interim Order for Use in Relation to COVID-19. Following these certifications, mass production is ongoing and distribution is under way in several countries. The MVM was designed, tested, prepared for certification, and mass produced in the space of a few months by a unique collaboration of respiratory healthcare professionals and experimental physicists, working with industrial partners, and is an excellent ventilator candidate for this pandemic anywhere in the world

Published
2021

30. Lp(a) levels: effects of progressive chronic renal failure and dietary manipulation.

Author

Monzani G, Bergesio F, Ciuti R, Ciciani AM, Martinelli F, Rosati A, and Salvadori M

Subjects
Adult, Aged, Amino Acids, Essential, Disease Progression, Female, Food, Fortified, Humans, Male, Middle Aged, Reference Values, Treatment Outcome, Diet, Vegetarian, Dietary Proteins administration & dosage, Kidney Failure, Chronic blood, Kidney Failure, Chronic diet therapy, Lipoprotein(a) blood
Abstract

Patients with chronic renal failure (CRF) have an increased risk of cardiovascular disease (CVD). Elevated lipoprotein(a) (LP(a)) levels have been shown to be an important risk factor for CVD. This study examined Lp(a) changes during the progression of renal disease in patients following different dietary regimens. Fifty-seven patients with CRF of different etiology and degree (mean age 58 +/- 10 yrs) were divided into four groups according to their serum creatinine (sCr) levels. The first group had sCr 1.5-3; the second 3-6; the third > 6, all on a conventional low-protein diet (CLPD), and the fourth had sCr > 6 on a supplemented vegetarian diet (SVD). Lp(a), apoproteins AI, B, E, CII, CIII, CII/CIII, Apo A/Apo B ratios and the lipid pattern (total cholesterol (TC) and its fractions LDL, HDL, HDL3 and triglycerides) were investigated. Patients with diabetes, proteinuria > 1.5 g/24 h, hepatic disease or taking contraceptives or lipid lowering drugs were excluded. Results were compared with a reference group (N = 12) with sCcr < 1. Lp(a) concentrations increased with the progression of renal failure, and a significant correlation was observed with sCr. Despite the elevated sCr levels, patients on the SVD had an almost normal Lp(a) concentration. Only 15% of the reference group had Lp(a) levels > 30 mg/dl, compared to 33%, 50% and 78% of the 1st, 2nd and 3rd groups and 38% of the 4th group. No relationship was found between Lp(a), lipids or apoproteins. Our results indicate that renal function influences Lp(a) levels and suggest a SVD helps to lower them. This might be ascribed to some antioxidant factors in the SVD.

Published
1997

31. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.

Author

Scaglione F, Scamazzo F, Arcidiacono MM, Cogo R, Monzani GP, and Fraschini F

Subjects
Adult, Bacterial Infections metabolism, Bacterial Infections microbiology, Bronchi metabolism, Bronchoalveolar Lavage Fluid chemistry, Chronic Disease, Ciprofloxacin blood, Ciprofloxacin pharmacokinetics, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Haemophilus influenzae drug effects, Humans, Male, Microbial Sensitivity Tests, Moraxella catarrhalis drug effects, Pefloxacin blood, Pefloxacin pharmacokinetics, Respiratory Tract Infections metabolism, Respiratory Tract Infections microbiology, Staphylococcus aureus drug effects, Bacterial Infections drug therapy, Ciprofloxacin therapeutic use, Pefloxacin therapeutic use, Respiratory Tract Infections drug therapy
Abstract

To determine the efficacy in vivo of pefloxacin and ciprofloxacin in the treatment of acute infectious bronchopneumopathies, 90 patients, suffering from acute exacerbation of chronic bronchitis and with no known allergies to quinolones, were admitted to the study. Patients were randomly divided into three groups of 30; the first group was dosed with pefloxacin 800 mg i.v. every 24 hours; the second group with pefloxacin 800 mg per os every 24 hours and the third with 500 mg per os of ciprofloxacin every 12 hours. Blood and bronchial secretion samples were simultaneously collected 2, 4, 8, 12, 14 and 24 hours after the first daily dose of antibiotic. Serum and bronchial secretion concentrations of pefloxacin and ciprofloxacin were determined by using a microbiological agar disk diffusion assay, employing Escherichia coli Kp 712 as test organism. Eradication of responsible microorganisms (Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis) were achieved in 98% of patients around 72 hours post treatment. Generally, both antibiotics expressed similar bactericidal properties when orally administered, while intravenous administration of pefloxacin displays a more rapid antibacterial action in comparison with the oral administration schedules. Maximal concentrations of both drugs in bronchial secretion were recorded at the same time after treatment (4 hours), with concentrations of about 2.5 micrograms/ml. Pefloxacin, having a longer half-life, was found 24 hours post-treatment with plasma concentrations of 1.5 micrograms/ml following a single oral dose of 800 mg. Ciprofloxacin, having a shorter half-life, showed a peak of about 1 microgram/ml, 12 hours after administration (500 mg/12 hours/os).

Published
1995
Full Text
View/download PDF

32. Lipids and apolipoproteins change during the progression of chronic renal failure.

Author

Bergesio F, Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V, and Salvadori M

Subjects
Adult, Aged, Creatinine blood, Female, Humans, Hyperlipidemias metabolism, Insulin blood, Kidney Failure, Chronic metabolism, Male, Middle Aged, Parathyroid Hormone blood, Apolipoproteins blood, Hyperlipidemias complications, Kidney Failure, Chronic etiology, Lipids blood
Abstract

Uremic hyperlipidemia was recently suggested to contribute to progression of chronic renal failure (CRF). To investigate the relationship between lipoprotein abnormalities and decline of renal function, plasma lipids with apoproteins A1, B, E, CII, CIII, CII/CIII and E/CIII ratios, parathyroid hormone (PTH), insulin and glucose levels were examined in 72 patients with different degrees of CRF and compared to 28 patients of a reference group. A significant decrease of CII/CIII ratio was already evident below a Ccr of 60 ml/min, while increased apo-CIII and triglycerides (TG) with reduced HDL-cholesterol (HDL-C) levels occurred below a Ccr of 30 ml/min. Both TG and apo-CIII showed a positive correlation with creatinine levels. On the contrary, apo-CII/apo-CIII and HDL-C inversely correlated with the progression of renal failure. PTH and insulin showed a positive correlation with TG, the former being also inversely related to apo-CII/apo-CIII ratio. Our results point to early apolipoprotein changes in the course of CRF. Elevated apo-CIII and reduced apo-CII/apo-CIII ratio may be considered the most typical features of uremic hyperlipidemia and likely account for the impaired TG removal and the hypertriglyceridemia (HTG). Secondary hyperparathyroidism may contribute to reduce peripheral lipolytic activity and cause HTG. A contributory role of hyperlipidemia in the progression of renal disease is also supported.

Published
1992

33. [Therapeutic effectiveness of bamifylline in elderly patients with COPD].

Author

Cogo R, Monzani GP, Fusillo M, and Vota M

Subjects
Aged, Dyspnea drug therapy, Dyspnea etiology, Female, Humans, Lung Diseases, Obstructive complications, Male, Respiratory Function Tests, Theophylline therapeutic use, Bronchodilator Agents therapeutic use, Lung Diseases, Obstructive drug therapy, Theophylline analogs & derivatives
Abstract

We studied the clinical and instrumental modifications of 20 patients (mean age: 67.95 +/- 1.23 years; 13 males, 7 females) suffering from COPD (less than 65% theoretical FEV1), during treatment with bamiphylline. At basal time, and after 1, 2, 3, 4, and 6 months of therapy we performed a clinical and spirometric examination. All spirometric parameters (FEV1, VC, MEF25-75, Tiffeneau Index) increased significantly (p less than 0.01 - ANOVA1) since the first control performed after 1 month of treatment. This trend was confirmed in the successive controls. Analogue results were observed for emogasanalytical (P-CO2-PO2) and clinical (cough and dyspnoea) parameters. During the experimental research we did not observe side effects due to the xanthine-derivative (bamiphylline) under study or modifications of the main haematochemical tests. Therefore we believe that bamiphylline must be considered an effective therapeutic tool for COPD therapy.

Published
1991

35. [Pulmonary tuberculosis in an immigrant population: the epidemiological aspects and clinical picture].

Author

De Luca P, Valentino E, Monzani GP, Gasparini A, and Cogo R

Subjects
Adolescent, Adult, Aged, Female, Humans, Italy epidemiology, Lung diagnostic imaging, Male, Middle Aged, Mycobacterium tuberculosis isolation & purification, Radiography, Sputum microbiology, Tuberculosis, Pulmonary diagnosis, Emigration and Immigration statistics & numerical data, Tuberculosis, Pulmonary epidemiology
Abstract

The number of extra European subjects coming to our country, in the last twenty years, is increased. This fact has contributed to enlarge the number of new cases of tuberculosis. In the present work we analyzed 54 extra European and 116 Italian patients with pulmonary tuberculosis observed in the last six years in our institute. The diagnosis was established by finding acid-fast bacilli in sputum and by clinical and radiographic patterns. We found that extra European subjects show disseminated and ulcerated forms in about 89% against approximately 40% viewed in Italian patients; while the cases of noncavitary tb in immigrants were about 11% against 60% in Italian population.

Published
1990

37. Biofiltration in elderly uremic patients.

Author

Grimaldi C, Ciccarelli C, Monzani G, Manescalchi F, Mancini G, and Frizzi V

Subjects
Acid-Base Equilibrium, Aged, Bicarbonates administration & dosage, Blood Chemical Analysis, Female, Humans, Hypotension prevention & control, Male, Time Factors, Blood, Renal Dialysis, Ultrafiltration methods
Abstract

We treated five elderly patients with conventional hemodialysis (CH) or biofiltration (BF) to establish whether their dialytic tolerance was better. For three patients treatment time was reduced from twelve to nine hours a week; for the other two, treatment time remained unchanged (10.5-12 h/week) because of their high interdialytic weight gain. At the beginning and end of the study, clinical status, biochemical data, nutritional status and acid-base balance (ABB) were checked. Plasma levels of small molecules, potassium and phosphate were unchanged for all patients. All had a lower number of episodes or less severe hypotension and good control of ABB. No patients had metabolic alkalosis or worsened nutritional status. For all patients BF was an efficacious choice compared to CH, giving them good health.

Published
1986

38. [Reversibility of obstructive kidney disease associated with renal insufficiency].

Author

Pizzarelli F, Sisca S, Monzani G, De Maio F, Delfino C, Primerano A, Mazzitelli R, Sergi I, Cozzupoli P, and Maggiore Q

Subjects
Adolescent, Adult, Aged, Child, Humans, Kidney Calculi surgery, Kidney Failure, Chronic etiology, Middle Aged, Nephrectomy, Acute Kidney Injury etiology, Urinary Calculi complications
Published
1976

Catalog

Books, media, physical & digital resources
See catalog results